Skip to content
Search to learn about InterSystems products and solutions, career opportunities, and more.
U.S. Health IT Community Positive on AI, but Fearful of “Data in the Wild”
During recent healthcare events, InterSystems conducted survey on current attitudes toward AI in healthcare. Topics included:

• Potential
• Current Adoption
• Challenges
• Risks

The results from 2024 VIVE and HIMSS conference attendees are detailed below.
InterSystems Booth from HIMSS 2024 - GenAI Survey on Digital Screen

Q1: Where does GenAI have the most potential in your organization?

Respondents skewed heavily toward two use cases: reducing burden and making important information visible. This aligns well with general industry tensions over clinician burnout and understaffing. When examined by sector, though, the results were less clear cut, indicating that the provider and government sectors contributed heavily to this skew.

Survey Results - Greatest Potential for AI

Figure 1: Views on Greatest Potential in Total and as Percentages by Industry Sector

Q2: What is your organization currently doing with GenAI?

Roughly one-third of respondents are watching and planning what to do with AI, while two-thirds are moving ahead testing, deploying, and developing capabilities. Again, there were definite differences by sector. Not surprisingly, the IT vendors in the sample are most aggressively moving forward, and government respondents are the most likely to be watching.

Survey Results - Current AI Adoption

Figure 2: Current Adoption Levels in Total and as Percentages by Industry Sector

Q3: What are the biggest challenges to be addressed with GenAI?

When asked about the biggest challenges to be addressed, the biggest news was in the low-ranking responses. Somewhat counter-intuitively, for an industry plagued by labor shortages, neither staffing nor costs received a lot of votes. Whereas ethical concerns, data readiness and biases were virtually tied for top choice. The most anomalous sector was the small payer sample, which was most concerned with data readiness, followed by technology costs.

Survey Results - Challenges Addressed with GenAI

Figure 3: Perceived Challenges in Total and as Percentages by Industry Sector

Q4: What is the greatest risk of abuse or harm from GenAI in healthcare?

When asked about risks, the overwhelming sentiment of respondents was that the greatest risk by far is that either through unconsented or unintended uses, patient health data will leak into the public domain. This was true across all sectors except for the 3% of respondents in the payer sector. That group was more concerned with the impact to human labor.

Survey Results - Greatest Risk of Abuse from GenAI in Healthcare

Figure 4: Greatest Risks in Total and as Percentages by Industry Sector


The overall sentiment of the audience was upbeat – when asked whether they viewed the technology pessimistically or optimistically, the average rating was a 4 out of 5, solidly positive. This audience also seems particularly concerned with getting it right – protecting patient records, addressing ethical and bias issues, and ensuring the data is ready for use.

InterSystems will continue collecting data throughout 2024 as AI moves from demo to widespread deployment across the healthcare sector.

Talk to us about GenAI

We’d love to talk. Fill in some details and we’ll be in touch.
*Required Fields
Highlighted fields are required
*Required Fields
Highlighted fields are required

By submitting your business contact information to InterSystems through this form, you acknowledge and agree that InterSystems may process this information, for the purpose of fulfilling your submission, through a system hosted in the United States, but maintained consistent with any applicable data protection laws.

** By selecting yes, you give consent to be contacted for news, updates and other marketing purposes related to existing and future InterSystems products and events. In addition, you consent to your business contact information being entered into our CRM solution that is hosted in the United States, but maintained consistent with applicable data protection laws.